Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

He, Yundong; Xu, Weidong; Xiao, Yu‐Tian; Huang, Haojie; Gu, Danan; Ren, Shancheng

doi:10.1038/s41392-022-01042-7

Cited by 78 publications

(74 citation statements)

References 569 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, we found that PSMA was a specific membrane marker for tip-like ECs in non-prostate cancers. PSMA is a type II transmembrane glycoprotein with folate hydrolase and N-acetylated-α-linked-acidic dipeptidase activities [37] . PSMA has been widely used as a target for the diagnosis and treatment of prostate cancer because of its high expression in prostate cancer cells [38] .…”

Section: Discussionmentioning

confidence: 99%

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues

Zhang

Lü

et al. 2023

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues

Zhang

Lü

et al. 2023

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

“…The role of estrogen receptors in PCa has been studied extensively, but remains a matter of debate (19,20). Considering that PCa tumor cells may use pathways other than those associated with androgen receptors as resistance mechanisms in advanced disease (21), it may be reasonable to evaluate the role of estrogen receptors in early-stage patients. A limited number of studies have investigated the role of estrogen receptors in PCa in non-metastatic castration-naive disease, and their results are conflicting (15)(16)(17).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of estrogen receptors in patients who underwent prostatectomy for non‑metastatic prostate cancer

et al. 2023

View full text Add to dashboard Cite

Estrogen receptors in prostate cancer (PCa) are a subject of debate. The aim of the present study was to investigate whether estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) impact the biochemical recurrence (BCR) of non-metastatic PCa after surgery. Following the application of the exclusion criteria, data from 108 patients who underwent laparoscopic radical prostatectomy between January 2011 and December 2019 were retrospectively evaluated. A total of 36 patients with BCR constituted the BCR group. The control group was formed using the Propensity Score Matching (PSM) method with a 1:2 ratio, including parameters with well-studied effects on BCR. The median follow-up time was 74.3 (range, 30-127.5) months in the BCR group and 66.6 (range, 31.5-130) months in the control group. Pathology specimens from the two groups were immunohistochemically stained with ERα and ERβ antibodies. Logistic regression analysis and survival analysis were performed. No differences in clinicopathological characteristics were detected between the two groups. The patients with ERα(-)/ERβ(+) staining results had a significantly fewer BCRs than other patients (P=0.024). In the logistic regression analysis, patients with ERα(-)/ERβ(+) PCa also had a significantly lower risk of recurrence (P= 0.048). In the survival analysis, the 5-year BCR-free survival rate of patients with ERα(-)/ERβ(+) PCa was higher than that of other patients (85.7 vs. 66.1%; P= 0.031). Excluding the effects of well-studied risk factors for recurrence by the PSM method, the present study showed that ERα and ERβ have prognostic value for non-metastatic PCa. The 5-year BCR-free survival rate is significantly higher in patients whose PCa tissue has ERα(-)/ERβ(+) staining results.

show abstract

“…However, due to advances in understanding genomic landscapes and biological functions, the treatment of PCa continues to evolve. Therefore, next-generation AR signaling inhibitors, bone-targeting agents and poly(ADP-ribose) polymerase (PARP) inhibitors, agents targeting other oncogenic signaling pathways, such as cyclin-dependent kinase (CDK)4/6, AKT, wingless-type protein (WNT), and epigenetic marks, have successively entered clinical trials [ 116 ].…”

Section: Aeds and Prostate Cancermentioning

confidence: 99%

From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer

Pellegrino

Ricci

Ceraldi

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer is a major health burden worldwide. Although the plethora of molecular targets identified in the last decades and the deriving developed treatments, which significantly improved patients’ outcome, the occurrence of resistance to therapies remains the major cause of relapse and mortality. Thus, efforts in identifying new markers to be exploited as molecular targets in cancer therapy are needed. This review will first give a glance on the diagnostic and therapeutic significance of histone deacetylase (HDAC) and voltage gated ion channels (VGICs) in cancer. Nevertheless, HDAC and VGICs have also been reported as molecular targets through which antiepileptic drugs (AEDs) seem to exert their anticancer activity. This should be claimed as a great advantage. Indeed, due to the slowness of drug approval procedures, the attempt to turn to off-label use of already approved medicines would be highly preferable. Therefore, an updated and accurate overview of both preclinical and clinical data of commonly prescribed AEDs (mainly valproic acid, lamotrigine, carbamazepine, phenytoin and gabapentin) in breast, prostate, brain and other cancers will follow. Finally, a glance at the emerging attempt to administer AEDs by means of opportunely designed drug delivery systems (DDSs), so to limit toxicity and improve bioavailability, is also given.

show abstract

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Cited by 78 publications

References 569 publications

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues

Prognostic value of estrogen receptors in patients who underwent prostatectomy for non‑metastatic prostate cancer

From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer

Contact Info

Product

Resources

About